Clinical trial
Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00110344 · Bayer, Industry · Terminated
Key facts
| NCT number | NCT00110344 |
|---|---|
| Title | Research Study for Patients With Metastatic Renal Cell Carcinoma |
| Official title | A Phase II Study of BAY 43-9006 Prior to and Following Nephrectomy in Patients With Metastatic Renal Cell Carcinoma. |
| Lead sponsor | Bayer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Nexavar (Sorafenib, BAY43-9006), Placebo |
| Enrollment | 1 |
| Start date | Nov 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | May 9, 2005 |
| Last update posted | Oct 11, 2013 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: